ITCI - Intra-Cellular Therapies Inc. Analyst Forecast Prices
This chart illustrates the current market value of Intra-Cellular Therapies (ITCI), which currently stands at 131.54, driven by high demand for Caplyta therapy. Patients with mental disorders remain loyal to the brand despite pricing pressure from Medicare. Intra-Cellular Therapies (ITCI) has earned recognition from psychiatrists as the creator of a safe method for treating schizophrenia, integrating its developments into global medical standards and establishing itself as a key hub of modern neuropharmacology.
Analytical breakdowns for Intra-Cellular Therapies (ITCI)
- price and consensus price forecast:
- market capitalization statistics:
- book capitalization information:
- debt obligations and liquidity statistics:
Debt to Equity Ratio Intra-Cellular Therapies|ITCI - Long-Term Debt to Capital|Current Liabilities to Capital intracellulartherapies.com|ITCI - Company Total Debt|Debts to Book Capitalization Intra-Cellular|ITCI - Company Long-Term Debt|Company Short-Term Loans and Borrowings Intra-Cellular Therapies|Immediate Liquidity intracellulartherapies.com
- business earnings and investment ratios data:
ITCI - Net Profit|Company Profit Forecast Intra-Cellular Therapies|ITCI - Price to Earnings Ratio|Price to Future Earnings Ratio intracellulartherapies.com|ITCI - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Intra-Cellular|ITCI - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Intra-Cellular Therapies|ITCI - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth intracellulartherapies.com|ITCI - Net earnings per share growth this year|Net earnings per one share growth forecast for next year Intra-Cellular Therapies
Summary company analytics:ITCI Intra-Cellular Therapies Inc.
The stability of the R&D workforce and sales growth at Intra-Cellular Therapies (ITCI) make the market's consolidated consensus target a key indicator of market optimism. This metric represents the weighted average of target prices from leading analysts, reflecting an aggregated assessment of the business's fair value; its deviation from current quotes helps investors determine the growth potential or the risk of asset overvaluation.
Competitors of Intra-Cellular Therapies
Analyst Median Target biogen.com|Neurocrine Biosciences, Inc. - Consensus Target|Analyst Forecast Prices RGC (Regencell Bioscience Ltd)|Axsome Therapeutics Inc - Analyst Consensus Forecast|ACADIA Corp (ACAD) - Consensus Target|XENE: Analyst Consensus Forecast|VKTX - Analyst Median Target|Price Target Chart Supernus|Broker Consensus Forecast CPRX (Catalyst Pharma)|Analyst Consensus Forecast DNLI|HRMY - Average Forecast Price|Biohaven Ltd. - Consensus Target|Analyst Consensus Forecast amylyx.com AMLX|TRVI - Price Target Chart|Fair Value Consensus PRAX (Praxis Precision Medicines Inc)|Anavex Corp (AVXL) - Price Target Chart|Average Forecast Price CeriBell EEG (CBLL)|PRTA (Prothena Corporation PLC) - Analyst Consensus Forecast|Alector Therapeutics (ALEC) - Analyst Median Target|Price Target Chart Annexon (ANNX)|omeros.com - Broker Consensus Forecast|Neurogene Corp - Consensus Target|Analyst Forecast Prices ACIU (AC Immune Inc)|VYGR - Price Target Chart|Fair Value Consensus NMRA (neumoratx.com)|SCLX: Analyst Consensus Forecast|Tevogen Bio Holdings Inc. (TVGN) - Analyst Consensus Forecast|Consensus Target ACOG|CGTX - Analyst Target Range|Analyst Consensus Forecast IKT|Consensus Target cassavasciences.com SAVA|Analyst Consensus Forecast ASRT (Assertio)|Coya Therapeutics Inc (COYA) - Average Forecast Price|VTGN - Price Target Chart|OVID: Price Target Chart|Acumen Pharmaceuticals (ABOS) - Price Target Chart|CRVO (cervomed.com) - Price Target Chart|Consensus Target ATHE|Analyst Consensus Forecast Clene Nanomedicine|Price Target Chart PepGen Inc. (PEPG)|Price Target Chart JUNS (jupiterneurosciences.com)|Analyst Consensus Forecast RLMD (Relmada Therapeutics)|Analyst Consensus Forecast annovisbio.com ANVS|GRCE - Price Target Chart|Fair Value Consensus AIFF (Firefly Neuroscience, Inc.)|KLTO (anewmeds.com) - Consensus Target|NeuroSense Therapeutics Ltd. - Fair Value Consensus|Consensus Target RVPH|MTVA (MetaVia, Inc.) - Analyst Forecast Prices|Analyst Consensus Forecast NRXS|HSDT (heliusmedical.com) - Fair Value Consensus|Analyst Consensus Forecast PASG (Passage Bio)|Neuphoria Therapeutics, Inc. (NEUP) - Average Forecast Price|NERV - Price Target Chart|Fair Value Consensus ATHA (athira.com)|ADXN: Analyst Consensus Forecast|Alzamend Neuro (ALZN) - Analyst Consensus Forecast|Price Target Chart Cyclerion Therapeutics Inc.|Protagenic - Forecast Levels Chart|Analyst Consensus Forecast KTTA|Analyst Median Target cortigent.com|Analyst Consensus Forecast ATXI (Avenue Therapeutics, Inc.)|Brainstorm Cell Therapeutics Inc. (BCLI) - Average Forecast Price|CARA - Price Target Chart|Analyst Median Target Chromocell CHRO|ELYM: Analyst Consensus Forecast|LBPH - Analyst Median Target|Consensus Target MRNS|NKGN (NKGen Biotech Inc) - Analyst Forecast Prices|Analyst Consensus Forecast NRBO|Consensus Target Sage Therapeutics Inc SAGE|Analyst Consensus Forecast SNPX (Synaptogenix, Inc.)|Analyst Median Target trevena.com (TRVN)|VIGL - Price Target Chart|WENA (Anew Medical Inc.) - Broker Consensus Forecast|CERE: Analyst Consensus Forecast
